Skip to content
Catalyst

pyridoxal 5'-phosphateFinding

Pyridoxal 5'-phosphate increases all-cause mortality

raisesVery limited evidenceFinding

01 · The sentence it was drawn from

“All-cause mortality was higher among patients assigned to MC-1 than placebo at 4 days (1.0% vs 0.3%; P = .03) but was similar at 30 days (1.9% vs 1.5%; P = .44).”
Quoted verbatim from Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
This finding among the 156 findings on its endpoint

pyridoxal 5'-phosphate

All-cause mortality

raises

Who
Intermediate- to high-risk patients undergoing CABG surgery with cardiopulmonary bypass; mortality at 4 days
Dose studied
MC-1 250 mg/d immediately before and for 30 days after surgery

Very limited evidencePMID 18381567 · 2008

02 · The study

Study
RCT
Duration
4 days

Evidence, by strength

  • strong
  • moderate
  • limited
  • very limitedthis finding
  • insufficient

03 · The paper

JAMA
What else it reported1 finding · 1 compound · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M70511ARQVCJTD2HTCPMEH6S